Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Jounce Therapeutics stock | 7.37

Own Jounce Therapeutics stock in just a few minutes.

Posted

Fact checked

Jounce Therapeutics, Inc is a biotechnology business based in the US. Jounce Therapeutics shares (JNCE) are listed on the NASDAQ and all prices are listed in US Dollars. Jounce Therapeutics employs 130 staff and has a trailing 12-month revenue of around USD$119.4 million.

How to buy shares in Jounce Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Jounce Therapeutics. Find the stock by name or ticker symbol: JNCE. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Jounce Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$7.37, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Jounce Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Jounce Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Jounce Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Jounce Therapeutics's share price has had significant positive movement.

Its last market close was USD$7.37, which is 28.36% up on its pre-crash value of USD$5.28 and 158.60% up on the lowest point reached during the March crash when the shares fell as low as USD$2.85.

If you had bought USD$1,000 worth of Jounce Therapeutics shares at the start of February 2020, those shares would have been worth USD$636.63 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,125.18.

Jounce Therapeutics share price

Use our graph to track the performance of JNCE stocks over time.

Jounce Therapeutics shares at a glance

Information last updated 2020-10-20.
Latest market close USD$7.37
52-week range USD$2.85 - USD$11.72
50-day moving average USD$8.7101
200-day moving average USD$6.1803
Wall St. target price USD$14.3
PE ratio 15.2615
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.628

Buy Jounce Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Jounce Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Jounce Therapeutics price performance over time

Historical closes compared with the close of $7.37 from 2020-11-16

1 week (2020-11-17) 3.95%
1 month (2020-10-23) -22.34%
3 months (2020-08-25) 41.73%
6 months (2020-05-23) N/A
1 year (2019-11-25) 54.83%
2 years (2018-11-23) 60.22%
3 years (2017-11-24) -51.92%
5 years (2015-11-23) N/A

Is Jounce Therapeutics under- or over-valued?

Valuing Jounce Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Jounce Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Jounce Therapeutics's P/E ratio

Jounce Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, Jounce Therapeutics shares trade at around 15x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Jounce Therapeutics's EBITDA

Jounce Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$22.6 million.

The EBITDA is a measure of a Jounce Therapeutics's overall financial performance and is widely used to measure a its profitability.

Jounce Therapeutics financials

Revenue TTM USD$119.4 million
Operating margin TTM 15.81%
Gross profit TTM USD$122 million
Return on assets TTM 6.75%
Return on equity TTM 20.05%
Profit margin 18.24%
Book value $3.736
Market capitalisation USD$339.4 million

TTM: trailing 12 months

Shorting Jounce Therapeutics shares

There are currently 1.6 million Jounce Therapeutics shares held short by investors – that's known as Jounce Therapeutics's "short interest". This figure is 20% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Jounce Therapeutics shares can be evaluated.

Jounce Therapeutics's "short interest ratio" (SIR)

Jounce Therapeutics's "short interest ratio" (SIR) is the quantity of Jounce Therapeutics shares currently shorted divided by the average quantity of Jounce Therapeutics shares traded daily (recently around 3.1 million). Jounce Therapeutics's SIR currently stands at 0.51. In other words for every 100,000 Jounce Therapeutics shares traded daily on the market, roughly 510 shares are currently held short.

However Jounce Therapeutics's short interest can also be evaluated against the total number of Jounce Therapeutics shares, or, against the total number of tradable Jounce Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Jounce Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Jounce Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.092% of the tradable shares (for every 100,000 tradable Jounce Therapeutics shares, roughly 92 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Jounce Therapeutics.

Find out more about how you can short Jounce Therapeutics stock.

Jounce Therapeutics share dividends

We're not expecting Jounce Therapeutics to pay a dividend over the next 12 months.

Jounce Therapeutics share price volatility

Over the last 12 months, Jounce Therapeutics's shares have ranged in value from as little as $2.85 up to $11.72. A popular way to gauge a stock's volatility is its "beta".

JNCE.US volatility(beta: 1.69)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jounce Therapeutics's is 1.6891. This would suggest that Jounce Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Jounce Therapeutics overview

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer. It is also developing JTX-4014, a clinical-stage anti-PD-1 antibody for combination therapy; and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment that is in the IND-enabling phase. The company's product candidate includes JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site